Notice of Allowability	Application No.	Applicant(s)	
	09/825,105	RUSSELL ET AL.	
	Examiner	Art Unit	
	Q. Janice Li	1632	
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED or other appropriate comm IGHTS. This application is) in this application. If not included munication will be mailed in due cours	se. THIS
1. This communication is responsive to <u>6/8/04 response</u> .			
2. The allowed claim(s) is/are <u>1-3,6 and 24-29</u> .			
3. \boxtimes The drawings filed on <u>03 April 2001</u> are accepted by the Ex	xaminer.		
 4. Acknowledgment is made of a claim for foreign priority una a) All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 	e been received. e been received in Applica cuments have been receiv of this communication to f	tion No ved in this national stage application fi	
5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give			E OF
6. CORRECTED DRAWINGS (as "replacement sheets") mus	st be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached			
1) 🗌 hereto or 2) 🗎 to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).			
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT I			he
·			
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	E □ Notice of	Information (DTO 450	•
Notice of References Cited (PTO-992) Notice of Draftperson's Patent Drawing Review (PTO-948)		Informal Patent Application (PTO-152 Summary (PTO-413),	<u>(1)</u>
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0	Paper No	o./Mail Date 's Amendment/Comment	
Paper No./Mail Date	<u></u>		
 Examiner's Comment Regarding Requirement for Deposit of Biological Material 	8.	's Statement of Reasons for Allowand Q. Janice Li Primary Examiner Art Unit: 1632	:e

Art Unit: 1632

DETAILED ACTION

The amendment and response filed 6/8/04 have been entered. Claims 1, 6, 24, and 27 have been amended. Claims 1-3, 6, and 24-29 are pending in the application and under current examination. Previous rejections are withdrawn in view of the amendment, arguments, and the following Examiner's amendment.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Benjamin A. Adler on September 3, 2004.

The claims have been amended as follows:

Claim 1. (currently amended) A method of inducing an immune response by administration of, wherein the method comprises administering mucosally to a subject a recombinant immunogen comprising a fusion protein containing a heterologous of an antigen of interest fused to the A2 and B subunits of a type II heat-labile enterotoxin.

Art Unit: 1632

Claim 24. (currently amended) A method of increasing Th1 response and cell-mediated immunity by administration of, wherein the method comprises administering mucosally to a subject a recombinant immunogen comprising a fusion protein containing a heterologous of an antigen of interest fused to the A2 and B subunits of a type II heat-labile enterotoxin.

In claim 26, "intramuscularly, transcutaneously and subcutaneously" were deleted.

Claim 27. (currently amended) A method of increasing Th1 response and cell-mediated immunity by administration of, wherein the method comprises administering mucosally to a subject a recombinant immunogen comprising a fusion protein containing a heterologous of an antigen of interest fused to the A2 and B subunits of a E. Coli heat-labile enterotoxin.

In claim 29, "intramuscularly, transcutaneously and subcutaneously" were deleted.

Conclusion

Claims 1-3, 6, and 24-29 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Q. Janice Li** whose telephone number is 571-272-0730.

Art Unit: 1632

The examiner can normally be reached on 9:30 am - 7 p.m., Monday through Friday, except every other Wednesday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Amy Nelson** can be reached on 571-272-0804. The fax numbers for the organization where this application or proceeding is assigned are **703-872-9306**.

Any inquiry of formal matters can be directed to the patent analyst, **Dianiece Jacobs**, whose telephone number is (571) 272-0532.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is **703-308-0196**.

Q. Janice Li Primary Examiner Art Unit 1632

September 7, 2004

Art Unit: 1632